CA3022358C - Methode pour le traitement de la sclerose en plaques - Google Patents

Methode pour le traitement de la sclerose en plaques

Info

Publication number
CA3022358C
CA3022358C CA3022358A CA3022358A CA3022358C CA 3022358 C CA3022358 C CA 3022358C CA 3022358 A CA3022358 A CA 3022358A CA 3022358 A CA3022358 A CA 3022358A CA 3022358 C CA3022358 C CA 3022358C
Authority
CA
Canada
Prior art keywords
group
carbon atoms
phenyl
diazepine
naphtho
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3022358A
Other languages
English (en)
Other versions
CA3022358A1 (fr
Inventor
Toshiyasu Imai
Toru Kawasaki
Toru Ogawa
Kazuhide Inoue
Original Assignee
Kyushu University NUC
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Nippon Chemiphar Co Ltd filed Critical Kyushu University NUC
Priority claimed from PCT/JP2017/016690 external-priority patent/WO2017188365A1/fr
Publication of CA3022358A1 publication Critical patent/CA3022358A1/fr
Application granted granted Critical
Publication of CA3022358C publication Critical patent/CA3022358C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne un médicament destiné à prévenir et/ou à traiter la sclérose en plaques, en particulier la douleur telle que la douleur neuropathique associée à la sclérose en plaques et similaire, ledit médicament contenant, comme principe actif, un composé présentant une activité antagoniste sur les récepteurs P2X4, par exemple un composé représenté par la formule générale (IH), ou un sel du composé, ou un hydrate ou un solvate du composé ou du sel.
CA3022358A 2016-04-28 2017-04-27 Methode pour le traitement de la sclerose en plaques Active CA3022358C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-090715 2016-04-28
JP2016090715 2016-04-28
PCT/JP2017/016690 WO2017188365A1 (fr) 2016-04-28 2017-04-27 Méthode pour le traitement de la sclérose en plaques

Publications (2)

Publication Number Publication Date
CA3022358A1 CA3022358A1 (fr) 2017-11-02
CA3022358C true CA3022358C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
AU2017255086B2 (en) Medicament for treatment of multiple sclerosis
US20230025452A1 (en) Anticancer combination therapy
ES2299888T3 (es) Pirid (2,3-d)pirimidin-2,4-diaminas como inhibidores de pde 2.
ES2699470T3 (es) Antagonistas de receptores
US11690911B2 (en) Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
AU2019233449B2 (en) Medicament for treating cough
US20200046684A1 (en) Anticancer combination therapy
US20180055851A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
TW200846329A (en) Compounds that modulate HSP90 activity
KR20190084292A (ko) HDM2-p53 상호작용 억제제에 대한 용량 및 요법
EP4440575A1 (fr) Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 et un inhibiteur de cdk4 pour le traitement du cancer
US20210128572A1 (en) Combination of atr kinase inhibitors with parp inhibitors
CA3022358C (fr) Methode pour le traitement de la sclerose en plaques
HK40005365A (en) Medicine for treating multiple sclerosis
JP7638864B2 (ja) 癌を処置するための組成物および方法
KR20080041177A (ko) 알킬퀴놀린 및 알킬퀴나졸린을 사용한 Ｆｌｔ３ 키나아제의상승적 변조
AU2019250696A1 (en) Pharmaceutical combination products comprising a histone deacetylase (HDAC) inhibitor and a TLR7 agonist and/or TLR8 agonist for the treatment of cancer
Gulec et al. Arginine vasopressin does not contribute to seizures induced by intracerebroventricularly-injected pilocarpine